相关实验视频

Updated: Jun 5, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

在先进的非小细胞肺癌中,第一线化疗加上免疫疗法后的免疫疗法超出了进展:一项回顾性研究

Xinyue Gu¹, Yue Hu¹, Ishanee Devi Mungur²

¹Cancer Center, Institute of Radiation Oncology, Hubei Key Laboratory of Precision Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.

Oncology letters

|December 16, 2024

概括

在晚期非小细胞肺癌 (NSCLC) 患者的疾病进展后 (IBP) 持续免疫治疗显示出改善的结果. 这一策略为在初始免疫疗法和化疗中进展的患者提供了可行的治疗选择.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
肺癌研究研究肺癌研究

背景情况:

免疫疗法在治疗晚期非小细胞肺癌 (NSCLC) 中取得了重大进展.
在最初接受免疫疗法与化疗相结合的患者中,在疾病进展后继续免疫疗法的疗效存在有限的数据.

研究的目的:

评估免疫疗法超出进展 (IBP) 在先进的NSCLC患者的疗效,在一线化疗免疫疗法后进展.

主要方法:

在初始化疗免疫治疗后进展的136名晚期NSCLC患者的回顾性审查.
卡普兰-梅尔关于无进展生存 (PFS) 和整体生存 (OS) 的生存分析.
逻辑等级测试和考克斯回归分析,以比较结果并确定独立的预后因素.

主要成果:

免疫治疗超出进展 (IBP) 组显示出更高的疾病控制率 (89.8%对70.8%,P=0.005).
在PFS2 (P=0.012) 和OS (P=0.041) 中观察到有利于IBP的统计学上显著的差异.
多变量分析确定IBP是改善PFS2的独立因素 (HR,0.613;P=0.022).

结论:

超出进展的免疫疗法 (IBP) 在晚期NSCLC中表现出良好的临床结果.
IBP是先进NSCLC患者的可行和有效的治疗选择,这些患者在初始化疗-免疫疗法中取得了进展.

关键词:

有效性有效性有效性.免疫疗法免疫疗法免疫治疗超出了进展的时间.非小细胞肺癌的肺癌.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...